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Mitochondrial diseases (MDs) are a heterogeneous group of progressive multisystem 
disorders caused by impaired mitochondrial function. This study aimed to evaluate 
the clinical course and long-term development of 53 pediatric patients with MDs. 
Developmental function was evaluated at nine time points (two pre-diagnosis, one 
at diagnosis, and six post-diagnosis), with the developmental quotient (DQ) from the 
Korean infant and child development test (KICDT) assessing a child’s developmental 
age (rather than chronological age). Additionally, disease-related clinical variables were 
reviewed, and clinical progress was determined through observation. Subgroup analyses 
by epilepsy severity, syndromic diagnosis, diffuse brain atrophy, and clinical rating were 
performed. The pre- and post-diagnosis results were compared by the paired t-test and 
Bonferroni correction. The pre-diagnostic, diagnostic, and post-diagnostic evaluations 
were compared using repeated measures ANOVA. Patients with diffuse brain atrophy 
at the first pre-diagnostic and second post-diagnostic evaluations showed lower DQs. 
Compared with patients with a mildly or severely deteriorating clinical course, those with 
an improving or static clinical course presented higher DQs at the pre-diagnostic and 
diagnostic evaluations. The age at onset of the first symptom correlated positively with the 
DQ post-diagnosis. Follow-up revealed consistent patterns of significant developmental 
deterioration during the lead time to diagnosis, with no significant decline post-diagnosis. 
The DQ is a feasible predictor and a measure of long-term functional development in 
children with MD. Early initiation of treatment may minimize developmental regression.
Keywords: mitochondrial disease, developmental quotient, metabolic disease, pediatric epilepsy, brain atrophy
inTrODUcTiOn
Mitochondrial diseases (MDs) vary considerably in terms of their manifestations and effects on dif-
ferent organ systems, as well as in terms of age of onset and rate of progression (1). Clinical pediatric 
reports have described the spectrum of signs and symptoms associated with MDs. Classification 
relies on accurate clinical, biochemical, and genetic information and may be based on either geno-
type or phenotype, but there is significant overlap. Although the prognosis for MD is dependent on 
the underlying diagnosis, there is large phenotypic variation (2, 3). Thus, the diagnostic evaluation 
is necessarily multitiered and broad based, with a focus on integrating information from many 
avenues (4). In particular, children with encephalopathy experience many limitations in daily 
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life (5). However, information on the long-term clinical course 
and developmental outcome of this heterogeneous group of 
diseases is lacking (5–7).
One of the key needs of families caring for children with rare 
metabolic or genetic impairments is to understand the long-term 
effect of the disorder on the child’s development (8). Specifically, 
a better understanding of the needs, problems, and long-term 
developmental trends of these children is essential for effective 
care planning and improving the quality of life (1).
Accordingly, the aims of this study were to evaluate the clinical 
course and long-term developmental trends in pediatric patients 
with MDs. The present study is the first to attempt to use a devel-
opmental scale for retrospectively assessing and describing the 
long-term developmental trends of children with MDs.
MaTerials anD MeThODs
Patients and Procedures
Data regarding pediatric patients were obtained from hospital 
records. Patient selection was based on both the diagnosis of 
MD and the results of a developmental evaluation using the 
developmental quotient (DQ). All patients were diagnosed with 
mitochondrial respiratory chain complex defects by biochemical 
enzyme assay of muscle tissue samples and satisfied the modified 
MD criteria proposed by Bernier et al. (9).
Standardized evaluations of developmental function were 
conducted. In addition, disease-related clinical variables were 
examined, including age at symptom onset, age at diagnosis, lead 
time to diagnosis, type of first symptom, lactic acidosis, patho-
logical features indicating myopathies, result of the biochemical 
enzyme assay for the mitochondrial respiratory chain complex, 
neuroimaging findings, and syndromic diagnosis.
Lead time to diagnosis was defined as the time between first 
symptom onset and diagnosis of MD. The severity of serum lactic 
acidosis was categorized as mild, moderate, or severe, based on 
the increase over normal reference values (≥2-fold, ≥3-fold, or 
≥4-fold increase). Normal reference range of lactate is known 
as 0.5–2.2  mmol/L (4). Myopathies were classified depending 
on whether abnormal pathology was detected only on one type 
of microscopy (one pathology) or on both light and electron 
microscopies (two pathologies). The diagnoses of mitochondrial 
encephalomyopathy, lactic acidosis, and stroke-like episodes 
(MELAS) and Leigh disease were based on the diagnostic 
criteria reported by Yatsuga et al. (10) and Rahman et al. (11), 
respectively. Involvement of the central nervous system, either 
with or without the involvement of other organs, was taken into 
consideration in assessing the severity of organ involvement in 
MD. The interpretation of patients’ diffuse brain atrophy on MRIs 
by the radiologist was reviewed, and the results were classified by 
three levels as no atrophy, mild atrophy, and severe atrophy by the 
pediatric neurologist.
The patients were divided into three groups based on the 
presence, severity, and intractability of epilepsy: patients without 
epilepsy; patients with drug-responsive epilepsy, defined as an 
epileptic condition responsive to antiepileptic treatment; and 
patients with drug-resistant epilepsy, requiring more than two 
tolerated and appropriately chosen and used antiepileptic drug 
schedules (12). Clinical progress was classified as improving, 
static, mildly deteriorating, or severely deteriorating, based on 
the changes in the clinical features of the patient, as observed 
by the treating clinician (modified from a previously published 
study) (13).
After the diagnosis of MD was confirmed, all patients were 
treated with mitochondrial cocktails such as coenzyme Q, 
carnitine, and various vitamins (14). All procedures conducted 
were approved by the institutional review board of Gangnam 
Severance Hospital in Seoul, Korea.
Measures of Developmental Function
Developmental function was evaluated using the Korean infant 
and child development test (KICDT). This test was developed 
by the Development Evaluation Enacting Subcommittee of the 
Korea Pediatrics Academy in February 2002. The KICDT uses 
a development index to assess the development of toddlers 
younger than 5 years of age, whose development level is below the 
expected based on their chronological age in months. The KICDT 
can be used to quickly screen toddlers who are suspected of hav-
ing delayed development or to observe toddlers who are already 
receiving treatment after positive diagnosis of delayed develop-
ment (15). The KICDT is a 140-item, clinician-rated inventory of 
skills designed to assess a child’s developmental age (rather than 
chronological age) in five functional domains: gross motor, fine 
motor, social-personal, language, and cognitive-adaptive skills.
The DQ was calculated for each KICDT domain using the 
following formula: DQ  =  (developmental age/chronological 
age) × 100. The mean of the five domain DQs was designated the 
overall DQ and was used as the primary index of the child’s over-
all developmental level. An overall DQ below 80 was regarded as 
abnormal.
The attending pediatricians administered the KICDT and 
obtained the DQ scores for a total of up to nine evaluations. 
Pre-diagnostic developmental evaluations were performed twice 
(the first visit prior to diagnosis, pre-first and the second visit 
prior to diagnosis, pre-second), followed by a one-time diagnos-
tic evaluation and six post-diagnostic developmental evaluations 
(the first visit after diagnosis, post-first; the second visit after 
diagnosis, post-second; the third visit after diagnosis, post-third; 
the fourth visit after diagnosis, post-fourth; the fifth visit after 
diagnosis, post-fifth; and the sixth visit after diagnosis, post-
sixth). To analyze the overall developmental trends, we included 
the results of the developmental evaluations at all nine time points. 
For further analyses (patient subgroups and DQ subdomains), 
only five DQ values at the following time points were used: two 
pre-diagnostic evaluations (pre-first and pre-second), one-time 
evaluation during the diagnosis, and two post-diagnostic evalua-
tions (post-first and post-second).
statistical analysis
Univariate (mean, SD, range) and multivariate (Pearson cor-
relation) descriptive statistics were used to analyze patients’ 
characteristics and clinical variables. In addition, Student’s t-test 
and the Mann–Whitney U-test (for non-parametric ordinal data) 
were performed to compare the subgroups in terms of epilepsy 
severity, syndromic diagnosis, diffuse brain atrophy, and clinical 
Table 2 | clinical progress of children with mitochondrial disease 
(n = 53).
characteristic Value
Number of organs involved 1.54 ± 0.93
Organ involvement CNS only 34 (64)
CNS + other organs 19 (36)
Severity of epilepsy No epilepsy 10 (19)
Drug-responsive epilepsy 18 (33)
Drug-resistant epilepsy 26 (48)
Diffuse brain atrophy on MRI Normal 22 (42)
Mild 26 (49)
Severe 5 (9)
Clinical progress Improving 1 (2)
Static 20 (38)
Mildly deteriorating 22 (42)
Severely deteriorating 10 (19)
Data given as total number (percentage) or mean ± SD.
CNS, central nervous system; MRI, magnetic resonance imaging.
Table 1 | Diagnostic evaluation of children with MD (n = 53).
characteristic Value
Male sex 32 (60)
Age at first symptom onset, years 0.95 ± 1.07
Age at diagnosis, years 3.12 ± 2.49
Lead time to diagnosis, years 2.17 ± 2.11
First symptom Seizure 26 (49)
Delayed development 22 (42)
Visual disturbance 1 (2)
Ataxia 1 (2)
Dystonia 1 (2)
Nystagmus 1 (2)
Hearing impairment 1 (2)
Lactic acidosis severity Normal 23 (43)
Mild 22 (42)
Moderate 7 (13)
Severe 1 (2)
Myopathies by pathologic 
features
Normal 10 (19)
One pathology 23 (43)
Two pathologies 20 (38)
Biochemical enzyme assay MRC I complex deficiency 48 (92)
MRC II complex deficiency 1 (2)
MRC IV complex deficiency 3 (6)
Syndromic diagnosis Leigh syndrome 11 (21)
MELAS 2 (4)
Non-specific MD 40 (76)
Data given as total number (percentage) or mean ± SD.
MD, mitochondrial disease; MRC, mitochondrial respiratory chain; MELAS, 
mitochondrial encephalopathy, lactic acidosis, and stroke-like episodes.
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rating. The paired t-test with Bonferroni correction was used to 
compare the results of the developmental function evaluations 
(overall DQ and DQ for each KICDT domain) at pre- and post-
diagnostic visits for various subgroups of patients and in the total 
cohort. Repeated measures ANOVA was performed to compare 
the evaluation results during the pre-diagnostic, diagnostic, and 
post-diagnostic visits. A post hoc test with Bonferroni adjustment 
was also conducted. IBM SPSS version 20.0 (IBM, Armonk, NY, 
USA) was used for data processing and analysis.
resUlTs
Patient characteristics
Our study included 53 children diagnosed with MD, whose 
developmental function had been assessed at several time 
points (pre-diagnosis, at diagnosis, and post-diagnosis) between 
March 2006 and February 2015. The lead time to diagnosis was 
1.09 ± 1.15 years (range, 0.6–1.46 years), and the follow-up dura-
tion from pre-first to post-second was 5.45 years.
Forty patients (76%) had been diagnosed with non-specific 
MD, 11 (21%) with Leigh syndrome, and 2 (4%) with MELAS. 
The mean age at the first onset of symptoms was 1.0 ± 1.1 years 
(range, 0–4.2 years), and 32 (60%) of the children were boys. The 
most common first symptom was seizure (26, 49%), followed by 
delayed development (22, 42%).
The majority of patients showed static (20, 38%) or mildly 
deteriorating (22, 42%) clinical progress, whereas the rest exhib-
ited severely deteriorating (10, 19%) or improving (1, 2%) clinical 
progress. More details of the clinical characteristics are presented 
in Tables 1 and 2.
effects of syndromic Diagnosis, Drug-
resistant epilepsy, Diffuse brain atrophy, 
and clinical rating
In patients diagnosed via syndromic diagnosis, no significant 
differences in DQ were observed between patients with Leigh 
disease and those with non-specific MD (Table 3). Patients with 
MELAS were excluded from this analysis because the small num-
ber of MELAS cases was insufficient for a meaningful statistical 
analysis. Similarly, no significant difference in DQ was noted 
between the subgroups of patients with various types of epilepsy 
severity (Table 3). However, the presence of diffuse brain atrophy 
was associated with significantly lower DQ levels of development 
at the pre-first (78.6 ± 20.0 vs 44.3 ± 35.3, p = 0.047) and post-
second evaluations (33.8 ± 10.0 vs 23.7 ± 13.4, p = 0.033), with 
similar but not statistically significant trends for the rest of the 
evaluations. Furthermore, DQ was significantly higher in patients 
with improving or static clinical progress than in patients with 
mildly deteriorating or severely deteriorating clinical progress at 
pre-second (68.5 ± 27.1 vs 39.70 ± 29.9, p = 0.002) and diagnosis 
(44.5 ± 22.8 vs 25.6 ± 23.4, p = 0.018).
effect of age at First symptom Onset and 
lead Time to Diagnosis
Age at the first symptom onset showed positive correlation with 
the level of developmental function at post-first (r  =  0.438, 
p = 0.047) and post-second (r = 0.619, p = 0.014). Lead time to 
diagnosis was negatively associated with DQ at all-time points, 
but this result did not reach statistical significance (Table 4).
long-term Developmental Trends in 
children with MDs
Long-term follow-up over the course of 7.70 years (from pre-first 
to post-sixth) showed declining trends over all studied periods 
(Figure 1). During the lead time to diagnosis, the slope of DQ 
Table 3 | Developmental quotient (DQ) for subgroups of children with mitochondrial disease (total, n = 53).
DQ syndromic diagnosis Drug-resistant epilepsy Diffuse brain atrophy clinical rating
leigh disease non-specific p no Yes p no Yes p improving-static Deteriorating p
Pre-
diagnostic 
evaluation
Pre-first 68.3 ± 35.4  
(n = 4)
52.5 ± 33.4  
(n = 14)
0.425 61.5 ± 30.4 
(n = 7)
52.6 ± 36.3 
(n = 11)
0.536 78.6 ± 20.0 
(n = 6)
44.3 ± 35.3 
(n = 11)
0.047* 66.9 ± 31.8  
(n = 9)
45.2 ± 33.2  
(n = 9)
0.177
Difference Pre-first  
vs Pre-second
23.6 ± 38.6  
(n = 4)
12.2 ± 20.4  
(n = 14)
0.433 27.2 ± 22.2 
(n = 7)
6.8 ± 23.6  
(n = 11)
0.151 17.0 ± 21.9 
(n = 6)
14.3 ± 27.9 
(n = 11)
0.841 7.1 ± 9.24  
(n = 9)
22.4 ± 32.7  
(n = 9)
0.207
Pre-second 55.8 ± 25.9 
(n = 11)
49.1 ± 33.7  
(n = 35)
0.545 54.2 ± 31.0 
(n = 23)
48.6 ± 33.1 
(n = 24)
0.632 63.9 ± 33.2 
(n = 16)
44.8 ± 30.1 
(n = 30)
0.055 68.5 ± 27.1  
(n = 19)
39.7 ± 29.9  
(n = 28)
0.002**
Difference Pre-second 
vs diagnosis
20.7 ± 16.2  
(n = 8)
16.7 ± 24.3  
(n = 24)
0.676 22.3 ± 18.4 
(n = 13)
16.4 ± 25.3 
(n = 20)
0.250 20.1 ± 24.8 
(n = 9)
18.6 ± 22.8 
(n = 23)
0.878 18.4 ± 18.0  
(n = 13)
18.9 ± 25.7  
(n = 20)
0.951
Diagnostic 
evaluation
Diagnosis 31.3 ± 26.3  
(n = 8)
32.5 ± 25.2  
(n = 29)
0.903 36.0 ± 23.6 
(n = 17)
30.4 ± 25.7 
(n = 22)
0.392 43.1 ± 19.3 
(n = 14)
26.7 ± 26.3 
(n = 24)
0.051 44.5 ± 22.8  
(n = 15)
25.6 ± 23.3  
(n = 24)
0.018*
Post-
diagnostic 
evaluation
Difference Diagnosis 
vs post-first
11.8 ± 7.5  
(n = 5)
5.4 ± 8.2  
(n = 14)
0.147 8.8 ± 9.1  
(n = 8)
4.1 ± 10.0  
(n = 13)
0.595 5.4 ± 15.9  
(n = 5)
5.7 ± 7.9  
(n = 15)
0.952 8.7 ± 9.9  
(n = 10)
3.3 ± 9.4  
(n = 11)
0.214
Post-first 30.2 ± 21.3  
(n = 5)
25.4 ± 25.3  
(n = 14)
0.709 27.4 ± 24.7 
(n = 8)
29.6 ± 25.8 
(n = 13)
0.697 44.0 ± 23.0 
(n = 5)
23.9 ± 24.9 
(n = 15)
0.130 38.0 ± 22.6  
(n = 10)
20.4 ± 24.6  
(n = 11)
0.106
Difference Post-first 
vs post-second
5.5 ± 5.0  
(n = 4)
11.3 ± 18.6  
(n = 10)
0.559 2.8 ± 4.2  
(n = 4)
12.1 ± 17.3 
(n = 11)
0.343 6.0 ± 6.7  
(n = 4)
12.4 ± 17.9 
(n = 10)
0.507 16.8 ± 23.2  
(n = 6)
4.9 ± 3.6  
(n = 9)
0.267
Post-second 17.0 ± 18.9  
(n = 4)
13.3 ± 13.7 
(n = 10)
0.687 13.6 ± 20.0 
(n = 4)
19.1 ± 19.2 
(n = 11)
0.343 33.8 ± 10.0 
(n = 4)
23.7 ± 13.4 
(n = 10)
0.033* 25.33 ± 15.9  
(n = 6)
12.43 ± 19.8  
(n = 9)
0.106
Data given as total number or mean ± SD. Non-parametric Mann–Whitney analysis with Bonferroni correction: *p < 0.05, **p < 0.01. Pre-first, first pre-diagnostic evaluation; pre-second, second pre-diagnostic evaluation; post-first, 
first post-diagnostic evaluation; post-second, second post-diagnostic evaluation.
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Table 4 | correlation between the developmental quotient (DQ) and age 
at symptom onset, age at diagnosis, and lead time to diagnosis.
DQ age at 
symptom 
onset
age at 
diagnosis
lead time to 
diagnosis
Pre-diagnostic 
evaluation
Pre-first 0.048 −0.283 −0.305
Pre-second 0.279 −0.104 −0.237
Diagnostic 
evaluation
Diagnosis 0.247 −0.086 −0.266
Post-diagnostic 
evaluation
Post-first 0.438* 0.225 −0.141
Post-second 0.619* 0.278 −0.188
Significant correlation: *p < 0.05.
Pre-first, first pre-diagnostic evaluation; pre-second, second pre-diagnostic evaluation; 
post-first, first post-diagnostic evaluation; post-second, second post-diagnostic 
evaluation.
FigUre 1 | long-term developmental trends in children with mitochondrial disease evaluated at nine time points over the course of 7.7 years. 
Development level is expressed in terms of developmental quotient (DQ). Pre-diagnostic developmental evaluations were performed twice (pre-first and pre-second), 
followed by a one-time diagnostic evaluation (Dx) and six post-diagnostic developmental evaluations (post-first, post-second, post-third, post-fourth, post-fifth, and 
post-sixth).
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declined significantly, reflecting a faster deterioration compared 
with that noted between diagnosis and post-first. The DQ 
declined steeply also between post-first and post-third. These 
declining patterns were comparable for the overall development, 
as well as for the five development subdomains describing gross 
motor, fine motor, social-personal, language, and cognitive-
adaptive skills.
The long-term follow-up over the course of 5.45 years (from pre-
first to post-second) showed consistent patterns of developmental 
deterioration (Table 5). Significant developmental deteriorations 
were noted for the overall DQ between pre-first and pre-second 
(difference, 14.7 ± 24.6, p = 0.021), as well as between pre-second 
and diagnosis (difference, 18.7 ± 22.7, p < 0.001). Similar patterns 
of developmental deteriorations were observed in terms of gross 
motor (difference: pre-first to pre-second, 10.7 ± 20.6, p = 0.042; 
pre-second to diagnosis, 13.7 ± 25.4, p = 0.004) and fine motor 
skills (difference: pre-first to pre-second, 12.6 ± 20.7, p = 0.020; 
pre-second to diagnosis, 17.9 ±  26.3, p <  0.001). In addition, 
evident developmental deteriorations were observed in terms 
of social–personal (difference, 20.2 ± 31.6, p < 0.001), language 
(difference, 21.5 ± 27.8, p < 0.001), and cognitive-adaptive skills 
(difference, 20.7 ± 27.9, p < 0.001), but only between pre-second 
and diagnosis. In contrast, no significant differences were found 
for the post-diagnostic evaluations (i.e., between diagnosis and 
post-first, and between post-first and post-second).
Table 6 | repeated measures anOVa for long-term development of 
various skills in children with mitochondrial diseases (n = 18).
DQ Difference p Difference (95% 
confidence interval)
Post hoc
Total <0.001
Pre-Dx 16.1 (6.3–25.8) 0.001**
Dx-post 7.7 (2.4–13.0) 0.004**
Gross motor <0.001
Pre-Dx 12.8 (1.8–23.8) 0.020*
Dx-post 6.8 (0.6–14.3) 0.080
Fine motor <0.001
Pre-Dx 16.2 (2.2–30.2) 0.020*
Dx-post 7.7 (1.0–16.4) 0.095
Social–
personal
<0.001
Pre-Dx 16.3 (0.8–31.8) 0.037*
Dx-post 11.4 (0.7–23.5) 0.071
Language <0.001
Pre-Dx 20.7 (6.1–35.2) 0.005**
Dx-post 4.3 (2.8–11.5) 0.381
Cognitive-
adaptive
0.001
Pre-Dx 15.3 (1.0–29.5) 0.033*
Dx-post 6.4 (2.7–15.6) 0.240
General linear model, repeated measures with Bonferroni adjustment: *p < 0.05, 
**p < 0.01. DQ, developmental quotient; pre, pre-diagnostic evaluation; post, post-
diagnostic evaluation; Dx, diagnostic evaluation.
Table 5 | evolution of DQ from the first pre-diagnostic evaluation to the second post-diagnostic evaluation, in terms of various skills of children with 
mitochondrial diseases (total, n = 53).
DQ subtrahend vs minuend n subtrahend Minuend Difference p
Total Pre-first vs pre-second 18 56.0 ± 33.5 41.3 ± 29.4 14.7 ± 24.6 0.021*
Pre-second vs diagnosis 33 48.8 ± 31.3 30.1 ± 25.0 18.7 ± 22.7 <0.001***
Diagnosis vs post-first 21 34.6 ± 26.2 28.8 ± 24.8 5.9 ± 9.8 0.013
Post-first vs post-second 15 27.3 ± 25.5 17.6 ± 18.9 9.7 ± 15.3 0.029
Gross motor Pre-first vs pre-second 18 53.1 ± 32.9 42.4 ± 31.4 10.7 ± 20.6 0.042*
Pre-second vs diagnosis 33 42.4 ± 32.8 28.7 ± 23.4 13.7 ± 25.4 0.004**
Diagnosis vs post-first 21 30.1 ± 22.1 26.0 ± 24.3 4.1 ± 14.7 0.223
Post-first vs post-second 15 25.7 ± 24.8 18.5 ± 18.2 7.1 ± 12.9 0.051
Fine motor Pre-first vs pre-second 18 50.9 ± 35.8 38.3 ± 27.6 12.6 ± 20.7 0.020*
Pre-second vs diagnosis 33 45.1 ± 34.1 27.2 ± 28.3 17.9 ± 26.3 <0.001***
Diagnosis vs post-first 21 32.7 ± 33.1 27.4 ± 28.0 5.2 ± 18.6 0.209
Post-first vs post-second 15 25.3 ± 27.8 15.7 ± 19.9 9.5 ± 18.1 0.062
Social–personal Pre-first vs pre-second 18 55.7 ± 39.1 40.2 ± 35.0 15.5 ± 31.6 0.053
Pre-second vs diagnosis 33 51.9 ± 35.9 31.6 ± 27.7 20.2 ± 31.6 <0.001***
Diagnosis vs post-first 21 34.9 ± 30.0 27.2 ± 24.3 7.7 ± 21.1 0.110
Post-first vs post-second 15 25.4 ± 23.6 15.2 ± 14.5 10.1 ± 21.6 0.104
Language Pre-first vs pre-second 18 56.4 ± 37.8 45.4 ± 31.7 10.9 ± 22.7 0.057
Pre-second vs diagnosis 33 52.6 ± 33.9 31.0 ± 27.6 21.5 ± 27.8 <0.001***
Diagnosis vs post-first 21 37.8 ± 30.2 33.1 ± 29.4 4.6 ± 10.7 0.064
Post-first vs post-second 15 32.8 ± 31.8 19.6 ± 23.4 13.2 ± 18.6 0.020
Cognitive-adaptive Pre-first vs pre-second 18 50.3 ± 39.3 38.6 ± 35.3 11.7 ± 31.3 0.131
Pre-second vs diagnosis 33 51.6 ± 37.1 30.8 ± 29.0 20.7 ± 27.9 <0.001***
Diagnosis vs post-first 21 35.8 ± 33.1 30.0 ± 29.2 5.8 ± 14.5 0.081
Post-first vs post-second 15 30.7 ± 31.1 21.4 ± 24.6 9.2 ± 16.1 0.051
Data given as total number or mean ± SD. Differences assessed via the paired t-test with Bonferroni correction: *p < 0.05, **p < 0.01, ***p < 0.001. Pre-first, first pre-Dx;  
pre-second, second pre-Dx; post-first, first post-diagnostic state; post-second, second post-diagnostic state; DQ, developmental quotient; Dx, diagnostic evaluation.
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long-term Development before and after 
Diagnosis
Repeated measures ANOVA revealed a significant difference in 
the rate of developmental decline for the pre- and post-diagnosis 
periods (p < 0.001). The subsequent post hoc test indicated that 
these differences were significant for all types of skills.
Repeated measures analysis showed a persistent pattern of 
developmental deterioration between the pre-diagnostic and 
post-diagnostic periods for overall development [difference, 16.1; 
95% confidence interval (CI), 6.3–25.8, p = 0.001], as well as gross 
motor (difference, 12.8; 95% CI, 1.8–23.8, p = 0.020), fine motor 
(difference, 16.2; 95% CI, 2.2–30.2, p = 0.020), social–personal 
(difference, 16.3; 95% CI, 0.8–31.8, p = 0.037), language (differ-
ence, 20.7; 95% CI, 6.1–35.2, p = 0.005), and cognitive-adaptive 
(difference, 15.3; 95% CI, 1.0–29.5, p = 0.033) skills (Table 6). The 
overall DQ showed a decline from the pre-diagnostic through 
the post-diagnostic periods, suggesting an overall deterioration.
DiscUssiOn
In the present study, the global developmental trends were evalu-
ated over a follow-up period of 7.70 years at nine time points and 
showed a decline over all periods. However, even with consist-
ently declining patterns, the characteristics of developmental 
deterioration were disparate. The overall developmental decline 
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pattern could be classified into five phases: (1) pre-diagnostic 
initial decline phase; (2) pre-diagnostic accelerated decline phase; 
(3) post-diagnostic alleviated phase; (4) post-diagnostic reac-
celerated decline phase; and (5) post-diagnostic stagnant phase.
Considering the pre-diagnostic phase as lead time, the DQ 
declined continuously, with the initial decline starting from the 
first onset of symptoms, followed by an accelerated deteriorating 
phase until diagnosis. During the initial period from diagnosis to 
the first post-diagnostic evaluation (~1 year), an impeded phase 
of developmental decline was noted, which appeared alleviated 
compared with the decline noted in previous phases. This was 
followed by an accelerated period of decline for ~2 years. Finally, 
~3 years after the diagnosis, the decline reached a stagnant phase. 
In this phase, the developmental deterioration appeared to be 
reaching the lowest and terminal level of 10% of the DQ. These 
declining patterns were similar for the overall development and 
all types of skills, including the gross motor, fine motor, social–
personal, language, and cognitive-adaptive. However, a more 
detailed analysis revealed that the delayed development in gross 
and fine motor skills exhibited more significant deterioration 
even in the pre-diagnostic initial decline phase.
In terms of the lead time, the developmental decline accelerated 
from the first onset of symptoms to the time of confirmation of 
diagnosis. In contrast, right after the diagnosis, a post-diagnostic 
alleviated phase was manifested. These facets of the develop-
mental course highlight the importance of shortening the lead 
time as well as of early detection of the first significant symptom. 
A shorter lead time is important in achieving a longer developmen-
tally alleviated phase or a prolonged period before reaching the 
stagnant phase and the lowest and terminal level of development.
As developmental delay is one of the first common symptoms 
in children with MD (16), vigilance and careful observation of 
any motor delay in children are integral to early diagnosis. With 
more structural attention and information, motor delays might 
be easier to detect by caregivers because of their comparatively 
evident developmental milestones in earlier childhood compared 
with language, cognitive, or social development (7). In addition, 
any motor delay is usually enough for a child to be referred to 
professionals, and additional signs of any developmental delays 
in the language, social, and cognitive domains should be further 
evaluated for etiological diagnosis. Hence, early detection of 
motor delay and other developmental signs of delay is important 
in children with MD to shorten the lead time.
Furthermore, the effects of diagnosis and intervention should 
not be overlooked in children with MD. Such a standardized 
screening tool to detect MDs early at patients’ routine visits to 
the pediatricians would be ideal. However, making the correct 
diagnosis is exceedingly problematic because of the heterogene-
ous features of this disorder (17, 18). MD may present at any 
age, with a spectrum of symptoms and signs, to several medical 
specialties. And there are no standard guidelines for the investiga-
tion of MD (2, 3). Diagnostic difficulty results not only from the 
wide spectrum of symptoms and signs that an individual patient 
may have but also from the absence of a reliable screening or 
diagnostic biomarker that is both sensitive and specific in all cases 
of MD (4). Discussion with a clinician who has expertise in MD is 
advised in order to guide investigation, in particular with respect 
to laboratory facilities and handling of specimens (2). Therefore, 
it might not be easy to adopt a standardized screening tool to 
detect them early in MD.
Confirming the diagnosis of MD is important to both the 
parents and physician, because confirmation of diagnosis could 
relieve the parents’ anxiety and helplessness caused by the uncer-
tainty of an undiagnosed condition and encourage them to seek 
various therapies for their children. For physicians, confirming 
the diagnosis of MD is fundamental in planning therapeutic 
intervention (17, 18).
The appearance of a post-diagnostic alleviated phase in this study 
is notable and possibly even inspiring to physicians who have only 
been using symptomatic or supportive treatment for MD. The pos-
sibility of a positive effect of the treatment on patients’ development, 
including mitochondrial cocktails, such as coenzyme Q, carnitine, 
and various vitamins, which were provided to the children with 
MD in this study, should not be dismissed. Notably, the children 
with MD in this study had been taking a mitochondrial cocktail 
immediately after receiving a confirmed diagnosis. Accordingly, 
the necessity of an early diagnosis, consecutive symptomatic treat-
ment, general supportive care, and early administration of possible 
medicine to shorten the lead time to diagnosis and alleviate the 
patients’ developmental regression is suggested.
We found that diffuse brain atrophy, the clinical rating provided 
by the physician, and the age at first symptom onset significantly 
affected the developmental level and decline. However, no signifi-
cant effect was noted for syndromic diagnosis and epilepsy severity, 
suggesting that these aspects may not directly reflect the develop-
mental condition of the patients. Because of the heterogeneous 
symptoms of MDs (14), syndromic diagnosis based on a combina-
tion of particular symptoms might not be strongly associated with 
the developmental function of children with MDs. Additionally, 
epilepsy-related factors are not the main factors that influence devel-
opmental function in such patients, but are nonetheless important 
manifestations of MDs (14). Instead, diffuse brain atrophy might 
largely account for the developmental level as a measure of brain 
function with structural change (16, 19). In particular, all pediatric 
patients included in the present study presented with central nerv-
ous system involvement. In addition, more than half had diffuse 
brain atrophy, which was associated with lower developmental level 
at all-time points and over all periods considered, from the early 
stage of the pre-diagnostic period through the lowest, stagnant, and 
terminal phase. The concept of clinical ratings (20) provided by the 
treating physician could be regarded as a good predictor of long-
term developmental prognosis because it reflects the characteristics 
of the patient’s general state and multiorgan involvement.
This study has several limitations. This is a preliminary study 
with a small number of patients, and the overall cohort was not 
followed up consistently since we reviewed the data retrospec-
tively. Moreover, in spite of the advantage of other developmental 
scales such as Bayley scale of Infants Development, KICDT was 
used as the most frequently and repeatedly used measure in out-
patient or inpatient clinical settings in the current study. It still has 
a strength as a possible long-term and repeatedly useful screening 
tool, however, other developmental measures might be able to 
give more reliable information about the patients’ developmental 
function. In addition, patients’ anthropometric values were not 
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included in the current study due to the small number of patients 
as a preliminary study. Despite such limitations, the present study 
addresses the lack of data regarding the long-term developmental 
trajectory and clinical course of pediatric patients with MDs, as 
such diseases are characterized by diverse and heterogeneous 
feature manifestations (7, 20, 21). Even a rough estimate of the 
long-term developmental trajectory of children with MD could 
provide important information for diagnosis and development 
of possible intervention plans. In future study, we hope that we 
could overcome this limitation on the heterogeneity of MD with 
a larger number of patients and include prospective data as well 
based on the understanding of developmental course of pediatric 
MD from current preliminary data.
Despite the study limitations, our findings highlight the 
importance of DQ in the prediction and rating of the long-term 
functional course of children with MD. There has been no other 
established predictor in terms of patient’s functional measure in 
pediatric MD because of its difficulties of expecting the clinical 
course. In the perspective of this limitation, development quo-
tient might be a candidate as a predictor or a measure in pediatric 
MD by giving the functional level of patients, which is a very 
meaningful value in pediatrics and could be obtained even from 
pediatric MD patients with much delayed developmental level. 
Our observations suggest that, upon confirmation of the diagno-
sis by the physician, measures, such as symptomatic treatment, 
general supportive care, and early administration of medicine, 
are encouraged to shorten the lead time to diagnosis and thereby 
minimize the patients’ developmental regression.
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